Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NGUYEN-STEVE D VU

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1427133347
CMS profile
337136
Location
ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$6,235.36

92 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NGUYEN-STEVE D VU

NPI 1427133347 · CMS profile ID 337136

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1427133347?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NGUYEN-STEVE D VU, NPI 1427133347, CMS profile ID 337136. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1427133347?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). NGUYEN-STEVE D VU, NPI 1427133347, CMS profile ID 337136. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1427133347?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
NGUYEN-STEVE D VU, NPI 1427133347, CMS profile ID 337136, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1427133347?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

92 matching records · $6,235.36 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 92 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–92 of 92.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Actelion Pharmaceuticals US, Inc. $27.3504/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885381787 CMS
Covis Pharma GmBH $22.9704/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 953397381 CMS
GlaxoSmithKline, LLC. $16.5204/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945100223 CMS
Actelion Pharmaceuticals US, Inc. $7.0304/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885381771 CMS
AstraZeneca Pharmaceuticals LP $12.5804/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915325299 CMS
AstraZeneca Pharmaceuticals LP $15.0904/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915672949 CMS
Actelion Pharmaceuticals US, Inc. $22.6904/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885381773 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.3004/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955867127 CMS
GlaxoSmithKline, LLC. $110.3804/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945100233 CMS
Genentech USA, Inc. $23.2804/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950787013 CMS
Philips Electronics North America Corporation $15.9103/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945620885 CMS
Philips Electronics North America Corporation $15.9103/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945620887 CMS
AstraZeneca Pharmaceuticals LP $21.2303/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914838167 CMS
Actelion Pharmaceuticals US, Inc. $26.4103/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885381765 CMS
GlaxoSmithKline, LLC. $23.5603/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945100225 CMS
Actelion Pharmaceuticals US, Inc. $31.5803/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885381791 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.2603/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887774309 CMS
Harmony Biosciences LLC $27.9503/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955143803 CMS
Merck Sharp & Dohme LLC $14.1903/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944756645 CMS
AstraZeneca Pharmaceuticals LP $12.7602/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915673059 CMS
GlaxoSmithKline, LLC. $8.3502/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945100215 CMS
GlaxoSmithKline, LLC. $0.6102/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945100217 CMS
AstraZeneca Pharmaceuticals LP $25.8102/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915147109 CMS
Actelion Pharmaceuticals US, Inc. $15.2902/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885381757 CMS
Gilead Sciences, Inc. $20.3502/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929533567 CMS
JAZZ PHARMACEUTICALS INC. $23.6602/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951345737 CMS
Actelion Pharmaceuticals US, Inc. $14.5702/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885381777 CMS
Baxter Healthcare $12.0402/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 888410315 CMS
GlaxoSmithKline, LLC. $18.4002/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945100213 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $12.4402/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887356683 CMS
Actelion Pharmaceuticals US, Inc. $23.9502/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885381789 CMS
Regeneron Healthcare Solutions, Inc. $18.3902/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927461585 CMS
Bayer HealthCare Pharmaceuticals Inc. $23.6202/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929852451 CMS
Harmony Biosciences LLC $45.3302/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955150307 CMS
GENZYME CORPORATION $13.0701/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938940813 CMS
AstraZeneca Pharmaceuticals LP $18.4301/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914909667 CMS
Electromed, Inc. $25.0301/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 948255333 CMS
Genentech USA, Inc. $19.7801/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950805681 CMS
AstraZeneca Pharmaceuticals LP $18.0501/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915732887 CMS
Actelion Pharmaceuticals US, Inc. $21.9301/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885381781 CMS
AstraZeneca Pharmaceuticals LP $17.7401/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915288403 CMS
Actelion Pharmaceuticals US, Inc. $29.7201/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885381783 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,245.56 140
PY2020 $8,770.90 80
PY2021 $12,271.21 106
PY2022 $6,235.36 92
PY2023 $403.81 5
PY2024 $1,592.49 13
PY2025 $114.30 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2022 Principal investigator $6,235.66 20
PY2021 Principal investigator $23,838.94 31

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

20 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Insmed, Inc. $47.31 07/22/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908159475
Principal investigator 1 Insmed, Inc. $47.31 07/22/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908159479
Principal investigator 1 Insmed, Inc. $71.02 07/22/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908160207
Principal investigator 1 Insmed, Inc. $71.02 07/11/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908148365
Principal investigator 1 Insmed, Inc. $117.00 07/11/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group PA
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908148669
Principal investigator 1 Insmed, Inc. $1,708.20 07/11/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908148741
Principal investigator 1 Insmed, Inc. $71.02 07/11/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908160389
Principal investigator 1 Insmed, Inc. $47.31 05/12/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908148667
Principal investigator 1 Insmed, Inc. $71.02 04/05/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908148359
Principal investigator 1 Insmed, Inc. $71.02 04/05/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908148361
Principal investigator 1 Insmed, Inc. $47.31 04/05/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908148363
Principal investigator 1 Insmed, Inc. $1,766.70 04/05/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908159469
Principal investigator 1 Insmed, Inc. $71.02 04/05/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908160201
Principal investigator 1 Insmed, Inc. $47.31 04/05/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908160211
Principal investigator 1 Insmed, Inc. $71.02 04/05/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908160217
Principal investigator 1 Insmed, Inc. $71.02 04/05/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908160395
Principal investigator 1 Insmed, Inc. $71.02 03/04/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908148355
Principal investigator 1 Insmed, Inc. $71.02 03/04/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908148357
Principal investigator 1 Insmed, Inc. $47.31 03/04/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908160401
Principal investigator 1 Insmed, Inc. $1,649.70 01/10/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908160197